Continuing-ops PBT fell 59.4% as $16.1m divestment gain lifted NPAT 16.6%

Profit before tax from continuing operations fell 59.4% to $12.6m from $31.0m, while reported NPAT grew 16.6% to $26.7m. The gap was filled by a $16.1m after-tax gain on the divested automation business and a lower effective tax rate of 15.8% versus 23.9% a year earlier. Revenue from continuing operations grew 5.7% to $263.2m.

Cash metrics improved sharply. Operating cash flow rose 41.2% to $57.1m, and cash on hand jumped to $64.1m from $18.8m, supported by divestment proceeds. The group remained debt-free, and total equity edged down 0.4% to $293.1m as distributions absorbed earnings.

The final dividend was lifted 47.3% to 18.43 cents per share, taking the payout ratio versus NPAT to 97.0% from 78.2%.

Segment results across the five reported business lines were broadly stable or improved modestly, with farm software margin expanding to 74.6% and NZ market genetics holding at 66.0%. Yet continuing-operations PBT collapsed from $31.0m to $12.6m, which means costs above the segment-result line rose sharply. The supplied release excerpts do not explain that gap.

The dividend is now stretched on a clean-earnings view. Continuing-operations profit after tax was $10.6m, well below the implied $25.5m dividend cost at 18.43 cents per share. The payout was funded from cash that included automation divestment proceeds, not from current-year continuing earnings. This matters because the automation revenue and any associated profit no longer recur in FY23.

Segment margins inside the continuing business are not uniformly healthy. Diagnostics margin compressed sharply to 39.7% from 45.4%, and herd testing margin fell to 54.0% from 56.8%. These are smaller segments, but combined with the unexplained rise in corporate costs they argue against treating 5.7% revenue growth as evidence of clean operating progress.

The interim context shows H1 NPAT of $50.8m (which included $15.2m of discontinued-operations gain), so the implied second-half NPAT of -$24.0m is distorted by divestment timing rather than being a clean operating signal. The 64.4% H1 revenue share is consistent with LIC's spring-biased artificial breeding cycle.

The release supports two reads. Cash and balance-sheet position have strengthened materially, so dividend funding capacity for FY23 is not in immediate doubt. But the underlying continuing-operations earnings power that should sustain a 97%-of-NPAT payout is not evident in this result, and the release does not address how it is expected to be restored.

Two items drive almost all of the growth: the $16.1m after-tax automation divestment gain, and an effective tax rate of 15.8% versus 23.9%. Strip both out and continuing-operations PBT fell to $12.6m from $31.0m, and continuing-operations profit after tax fell to $10.6m from $23.6m. The release excerpts do not explain the lower tax rate.

The cash result is higher-quality. Operating cash flow of $57.1m comfortably exceeded both reported and continuing-operations earnings. The $45.3m rise in cash on hand reflects genuine operating cash generation plus divestment proceeds rather than working-capital releases — receivable days actually lengthened to 66.8 from 63.0, while inventory days fell to 15.3 from 19.9, leaving operating working capital roughly $2.6m higher.

The segment picture is mixed: farm software and the dominant NZ market genetics segment held up, but diagnostics and herd testing margins compressed and the unallocated cost line moved adversely enough to swing continuing-operations PBT down by $18.4m.

This briefing cannot assess management's explanation of the unallocated-cost increase or the forward earnings shape, because no FY23 guidance or directors' commentary on these items is supplied.